Tag: Osteoporosis
Review Spotlights Optimal Care of T2DM + Osteoporosis
Preferred T2DM meds are sulfonylureas, DPP-4is, GLP-1 receptor agonists
ACP: Recommendations Updated for Low Bone Density Treatment
Osteoporotic women should be treated with pharmacologic therapy for 5 years to cut fracture risk
Osteoporosis Tx Ups Survival in Postmenopausal Breast Cancer
Improved event-free survival, distant disease-free survival among postmenopausal breast CA patients
Older Women Show Limited Understanding of Osteoporosis
Even after an osteoporosis-related fracture, few women are on pharmacotherapy
AAOS: Osteoporosis Fractures More Often Fatal for Men
Mortality rate 18.7 percent for men, 13.9 percent for women year after fracture
Findings Support Bisphosphonate Use in Men With Osteoporosis
Reduced risk seen for vertebral and possibly nonvertebral fractures
Summer Concentrations of 25OHD Predict Bone Mineral Density
Low serum 25OHD concentrations during summer linked to increased relative risk of osteoporosis
ASBMR: Romosozumab Linked to Reduced Fracture Risk
Reduced vertebral fracture risk at 12 months among postmenopausal women with osteoporosis
Abaloparatide Reduces Fracture Risk in Women With Osteoporosis
Medication appears to reduce fractures better than teriparatide or placebo, researchers say
Osteoporosis Treatment-Linked Changes in BMD ID Fracture Risk
Treatment-related increases in total hip bone mineral density linked to reduced fracture risk
